Julio Plaza-Diaz, Marco Brandimonte-Hernandez, Bricia Lopez-Plaza, Francisco Javier Ruiz-Ojeda, Ana Isabel Alvarez-Mercado, Lucia Arcos-Castellanos, Jaime Feliu-Batlle, Thomas Hummel, Samara Palma-Milla, Angel Gil
{"title":"Effect of a novel food rich in miraculin on the intestinal microbiome of malnourished patients with cancer and dysgeusia","authors":"Julio Plaza-Diaz, Marco Brandimonte-Hernandez, Bricia Lopez-Plaza, Francisco Javier Ruiz-Ojeda, Ana Isabel Alvarez-Mercado, Lucia Arcos-Castellanos, Jaime Feliu-Batlle, Thomas Hummel, Samara Palma-Milla, Angel Gil","doi":"10.1101/2024.08.20.24312287","DOIUrl":null,"url":null,"abstract":"Dysgeusia contributes to nutritional derangement and worsens the quality of life of patients with cancer. Despite the different strategies, there is no effective treatment for patients suffering from taste disorders provided by the pharmaceutical industry. We developed a novel strategy for re-ducing side effects in cancer patients by providing a novel food supplement with the taste-modifying glycoprotein miraculin, which is approved by the European Union, as an adju-vant to medical-nutritional therapy. A pilot randomized, parallel, triple-blind, and place-bo-controlled intervention clinical trial was carried out in which 31 malnourished patients with cancer and dysgeusia receiving antineoplastic treatment, and were randomized into three arms: standard dose of DMB (150 mg DMB/tablet), high dose of DMB (300 mg DMB/tablet) or placebo (300 mg freeze-dried strawberry) for three months. Patients consumed a DMB or placebo tablet before each main meal (breakfast, lunch and dinner). Using stool samples from patients with can-cer, we analyzed the intestinal microbiome via nanopore methodology. We detected differences in the relative abundances of genera Phocaeicola and Escherichia depending on the treatment. Nev-ertheless, only the Solibaculum genus was more abundant in the standard-dose DMB group after 3 months. At the species level, Bacteroides sp. PHL 2737 presented a relatively low abundance in both DMB groups, and Vescimonas coprocola presented a relatively high abundance in both treat-ment groups after 3 months. Furthermore, a standard dose of DMB was positively associated with TNF-α levels and Lachnoclostridium and Mediterraneibacter abundances, whereas a high dose of DMB was negatively associated with TNF-α levels and the relative abundance of Pho-caeicola. After a high dose of DMB, erythrocyte polyunsaturated fatty acids were positively cor-related with Lachnoclostridium and Roseburia, and there was a positive association between Pho-caeicola and the acetic acid concentration of feces. The intake of DMB together with nutritional treatment and individualized dietary advice results in positive changes in the intestinal micro-biome of patients with cancer and dysgeusia There was a negative association between the rela-tive abundance of Phocaeicola and taste perception in the DMB high dose group. Changes observed in the intestinal microbiota might contribute to maintaining an appropriate immune response of cancer patients. Since the present pilot study involved only a few participants, further research is needed to draw robust conclusions.","PeriodicalId":501437,"journal":{"name":"medRxiv - Oncology","volume":"63 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.08.20.24312287","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Dysgeusia contributes to nutritional derangement and worsens the quality of life of patients with cancer. Despite the different strategies, there is no effective treatment for patients suffering from taste disorders provided by the pharmaceutical industry. We developed a novel strategy for re-ducing side effects in cancer patients by providing a novel food supplement with the taste-modifying glycoprotein miraculin, which is approved by the European Union, as an adju-vant to medical-nutritional therapy. A pilot randomized, parallel, triple-blind, and place-bo-controlled intervention clinical trial was carried out in which 31 malnourished patients with cancer and dysgeusia receiving antineoplastic treatment, and were randomized into three arms: standard dose of DMB (150 mg DMB/tablet), high dose of DMB (300 mg DMB/tablet) or placebo (300 mg freeze-dried strawberry) for three months. Patients consumed a DMB or placebo tablet before each main meal (breakfast, lunch and dinner). Using stool samples from patients with can-cer, we analyzed the intestinal microbiome via nanopore methodology. We detected differences in the relative abundances of genera Phocaeicola and Escherichia depending on the treatment. Nev-ertheless, only the Solibaculum genus was more abundant in the standard-dose DMB group after 3 months. At the species level, Bacteroides sp. PHL 2737 presented a relatively low abundance in both DMB groups, and Vescimonas coprocola presented a relatively high abundance in both treat-ment groups after 3 months. Furthermore, a standard dose of DMB was positively associated with TNF-α levels and Lachnoclostridium and Mediterraneibacter abundances, whereas a high dose of DMB was negatively associated with TNF-α levels and the relative abundance of Pho-caeicola. After a high dose of DMB, erythrocyte polyunsaturated fatty acids were positively cor-related with Lachnoclostridium and Roseburia, and there was a positive association between Pho-caeicola and the acetic acid concentration of feces. The intake of DMB together with nutritional treatment and individualized dietary advice results in positive changes in the intestinal micro-biome of patients with cancer and dysgeusia There was a negative association between the rela-tive abundance of Phocaeicola and taste perception in the DMB high dose group. Changes observed in the intestinal microbiota might contribute to maintaining an appropriate immune response of cancer patients. Since the present pilot study involved only a few participants, further research is needed to draw robust conclusions.